Find verified Capmatinib hydrochloride API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Capmatinib hydrochloride for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Capmatinib hydrochloride API.
Alternate Names: Tabrecta, Capmatinib dihydrochloride hydrate
CAS No: 1865733-40-9
PubChem CID: 122201352
Mol Formula: C23H21Cl2FN6O2
Mol Weight: 503.4 g/mol
IUPAC Name: 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;hydrate;dihydrochloride
Drug Class: Kinase inhibitors, Tyrosine Kinase Inhibitors
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Synthetic APIs
API Description: Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
